451 related articles for article (PubMed ID: 28919062)
1. Progress and challenges in anti-obesity pharmacotherapy.
Bessesen DH; Van Gaal LF
Lancet Diabetes Endocrinol; 2018 Mar; 6(3):237-248. PubMed ID: 28919062
[TBL] [Abstract][Full Text] [Related]
2. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Srivastava G; Apovian C
Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of Obesity and Pharmacologic Treatment Options.
Shettar V; Patel S; Kidambi S
Nutr Clin Pract; 2017 Aug; 32(4):441-462. PubMed ID: 28632997
[TBL] [Abstract][Full Text] [Related]
4. Update on obesity pharmacotherapy.
Bray GA; Ryan DH
Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for obesity.
Wilding JP
J Psychopharmacol; 2017 Nov; 31(11):1503-1508. PubMed ID: 29132230
[TBL] [Abstract][Full Text] [Related]
6. Interface between pharmacotherapy and genes in human obesity.
O'Connor A; Swick AG
Hum Hered; 2013; 75(2-4):116-26. PubMed ID: 24081227
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
8. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
Krentz AJ; Fujioka K; Hompesch M
Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
[TBL] [Abstract][Full Text] [Related]
9. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
[TBL] [Abstract][Full Text] [Related]
10. Do we need anti-obesity drugs?
Hainer V; Hainerová IA
Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():8-20. PubMed ID: 23280861
[TBL] [Abstract][Full Text] [Related]
11. Anti-obesity drugs: a review about their effects and their safety.
Derosa G; Maffioli P
Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
[TBL] [Abstract][Full Text] [Related]
12. Do the Natural Chemical Compounds Interact with the Same Targets of Current Pharmacotherapy for Weight Management?-A Review.
Luo S; Lenon GB; Gill H; Yuen H; Yang AWH; Hung A; Nguyen LT
Curr Drug Targets; 2019; 20(4):399-411. PubMed ID: 30173643
[TBL] [Abstract][Full Text] [Related]
13. New advances in models and strategies for developing anti-obesity drugs.
Kim GW; Lin JE; Blomain ES; Waldman SA
Expert Opin Drug Discov; 2013 Jun; 8(6):655-71. PubMed ID: 23621300
[TBL] [Abstract][Full Text] [Related]
14. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857
[TBL] [Abstract][Full Text] [Related]
15. Medication-Assisted Weight Loss in the Age of Obesity.
Leahy LG
J Psychosoc Nurs Ment Health Serv; 2017 Aug; 55(8):21-26. PubMed ID: 28771283
[TBL] [Abstract][Full Text] [Related]
16. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice.
Gadde KM
Expert Opin Pharmacother; 2014 Apr; 15(6):809-22. PubMed ID: 24548209
[TBL] [Abstract][Full Text] [Related]
17. Anti-obesity drugs: status quo and recent advances.
Zhu HJ; Jin ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Jun; 33(3):243-7. PubMed ID: 21718603
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
19. [The pharmacotherapy of obesity].
Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G
Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782
[TBL] [Abstract][Full Text] [Related]
20. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
Scheen AJ; Van Gaal LF
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
